Related references
Note: Only part of the references are listed.Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients
Steve Trifilio et al.
CANCER (2007)
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial
Thomas J. Walsh et al.
CLINICAL INFECTIOUS DISEASES (2007)
Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy
S. M. Trifilio et al.
BONE MARROW TRANSPLANTATION (2007)
Recombinant interferon γ1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions
Amar Safdar et al.
CANCER (2006)
Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions
II Raad et al.
CLINICAL INFECTIOUS DISEASES (2006)
Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection
AJ Ullmann et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections
A. Safdar
BONE MARROW TRANSPLANTATION (2006)
Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani
K Heyn et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Interferon-γ and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important Zygomycetes
C Gil-Lamaignere et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Oral bioavailability of posaconazole in fasted healthy subjects - Comparison between three regimens and basis for clinical dosage recommendations
F Ezzet et al.
CLINICAL PHARMACOKINETICS (2005)
Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults
R Courtney et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
R Herbrecht et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.
S Arikan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Share Paper
